Smoldering Multiple Myeloma
Pipeline by Development Stage
Drug Modality Breakdown
Smoldering Multiple Myeloma is a $3.9B market dominated by a single asset approaching loss of exclusivity.
Key Trends
- Market concentration risk: 99.6% of spending on one product (REVLIMID)
- Patent cliff approaching March 2028 with $3.9B revenue at risk
- Phase 2 pipeline activity (22 trials) suggests competitive repositioning underway
Career Verdict
Proceed cautiously; this is a consolidating, high-risk market facing imminent generic competition with limited pipeline depth to offset revenue erosion.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | REVLIMID (lenalidomide) | Bristol Myers Squibb | $3.9B | 99.6% | LOE_APPROACHING | Declining | 1.7yr |
| 2 | KYPROLIS (carfilzomib) | Dr. Reddy's Laboratories | $14M | 0.4% | PEAK | Stable | 7.1yr |
Drug Class Breakdown
Approaching patent cliff; generic competition imminent
Minimal market penetration
Career Outlook
DecliningThe smoldering myeloma market is contracting due to imminent generic competition against REVLIMID, with limited pipeline innovation to sustain revenue. BMS's commercial footprint will likely shrink significantly after 2028, reducing career stability in sales, marketing, and manufacturing roles. This is a consolidating market with high employment churn risk.
Breaking In
Consider entry-level roles in Clinical Operations or Medical Affairs only if pursuing specialized hematology-oncology expertise that transfers across indications; avoid pure commercial roles (sales, marketing) in this indication.
For Experienced Professionals
Experienced professionals should negotiate retention packages now or explore lateral moves to BMS's higher-growth oncology franchises (e.g., cell therapy, solid tumors); manufacturing engineers should emphasize process optimization and cost-reduction credentials for post-LOE restructuring.
In-Demand Skills
Best For
Hiring Landscape
Bristol Myers Squibb is actively hiring across 720 positions, with Manufacturing representing 49% of open roles ($184K avg) and Medical Affairs second at 12% ($206K avg). Clinical Operations commands the highest compensation at $265K average, reflecting specialized expertise demand. However, hiring may contract sharply post-2028 patent expiration.
Top Hiring Companies
By Department
Manufacturing and commercial roles offer stable near-term compensation, but lack long-term security; prioritize roles with transferable skills or positions in pipeline development teams.
Competitive Landscape
9 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 19 trials with date data
Clinical Trials (22)
Total enrollment: 801 patients across 22 trials
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma
PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines
Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
A Phase II Study of BI-505 in Smoldering Multiple Myeloma
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma
Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma
A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.
Expanded Access Treatment Protocol CA204-143
Early Patient Access Treatment Use Protocol CA204-220
Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma
Related Jobs in Oncology
Customer Service Representative
Sr. Account Manager - Molecular Instruments
Area Sales Manager
Data & AI Product Owner – Quality
Manufacturing Technician II, POROS Manufacturing (Rotating Weekends, Day Shift)
Sr QC Technician
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.